News

Agios Appoints Jeffrey Capello to Board of Directors

– Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023…

2 years ago

Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023

CHATHAM, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced…

2 years ago

IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days

MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…

2 years ago

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to…

2 years ago

Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial

Presentation of data from ReSPECT-GBM Phase 1/2a and Phase 2b trials expected second half of 2023AUSTIN, Texas, April 19, 2023…

2 years ago

Celebrate 420 with Good Supply!

Enjoy a Blast of Summer Nostalgia with Good Supply’s New Product Lineup Now Available Across CanadaTORONTO, April 19, 2023 (GLOBE…

2 years ago

EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023

Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells…

2 years ago

SOLVE FSHD invests in Epic Bio for the development of a novel treatment for Facioscapulohumeral Muscular Dystrophy

Investment will further accelerate the development of EPI-321VANCOUVER, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture-philanthropic…

2 years ago

H1.co Named 2023 Website of the Year by the Health And IT Marketing Community

H1’s new brand strategy and website recognized by HITMC for its visual appeal and stellar contentNEW YORK, April 18, 2023…

2 years ago

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic resistance Combination was well-tolerated; supports…

2 years ago